ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 13
HERTHENA-Lung02 Trial: Exploring the Role of Patritumab Deruxtecan in Advanced EGFR-Mutant NSCLC
This episode summarizes the HERTHENA-Lung02 trial and examines the average duration of response to platinum-based chemotherapy in patients with advanced EGFR-mutated NSCLC who have previously undergone multiple lines of EGFR TKI therapy, discusses strategies for community oncologists to tackle diverse resistance mechanisms to third-generation TKIs, and evaluates the importance of tolerability in sparing platinum-based chemotherapy compared with using ADCs in subsequent treatment lines.
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Please summarize the HERTHENA-Lung02 trial. In your experience, what is the average DOR among your patients with platinum-based chemotherapy on or after treatment with at least 1 line of EGFR TKI therapy for advanced or metastatic EGFR-mutated NSCLC?
How might community oncologists address the diverse mechanisms of resistance to third-generation TKIs to optimize subsequent treatment aftermultiple lines of prior therapy for advanced or metastatic NSCLC with AGAs?
From a tolerability perspective, how important is sparing platinum-based chemotherapy in subsequent lines of therapy vs an ADC?